LAFAYETTE – University Hospital & Clinics (UHC), in conjunction with Cancer Center of Acadiana (CCA), is seeking women aged 18 years and older with previously untreated breast cancer to participate in a clinical trial.

This research study will assess the effectiveness of an investigational antibody in combination with standard first-line treatment in patients with metastatic, or locally advanced, triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (MBC).  This is a Phase III clinical trial.  Drugs that successfully pass Phase III are usually approved for use in the general population by the national regulatory authority.

Medical Oncologist John M. Rainey, M.D., Director of Oncology and Oncological Research at UHC, will preside over this study.

UHC participates in clinical trials and studies to help improve future patient care and disease prevention.  Clinical trials offer patients the opportunity to have access to experimental treatments and drugs that may or may not improve their health.  Trials also help expand knowledge about the best ways to treat cancer.

Clinical trials also empower a patient who may not be responding ideally to treatment to make his or her own decision.  Physicians, nurses and other team members at UHC will thoroughly instruct a patient on potential risks and benefits of participating in a clinical trial.  The staff will then closely monitor and assess the progress of the trial and continue this through follow-up care.

When patients participate in a clinical trial, they are not only advancing medical technology, they are providing a valuable benefit to future generations.

For more information on this and other clinical trials available, call (337) 289-8658 or visit LafayetteGeneral.com/ClinicalTrials.